Stephen Syler
Family Medicine · Tell City, INNPI 1801882857
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 527 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 527 payments — averaging $15.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- AbbVie$838
- Amgen$570
- GSK$536
- Amarin Pharma, Inc.$377
- plus $4K from 36 others
What the payments were for
- Food & beverage$7,89898%
- Education$1892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,086 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 127 | $210,255 |
| EliquisApixaban | 120 | $131,181 |
| FarxigaDapagliflozin Propanediol | 126 | $130,934 |
| MounjaroTirzepatide | 72 | $86,708 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $67,860 |
| JardianceEmpagliflozin | 37 | $59,930 |
| XareltoRivaroxaban | 72 | $55,073 |
| RybelsusSemaglutide | 22 | $43,658 |
| MyrbetriqMirabegron | 28 | $23,389 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $22,842 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $21,739 |
| EntrestoSacubitril/Valsartan | 21 | $20,629 |
| LinzessLinaclotide | 25 | $16,520 |
| TrintellixVortioxetine Hydrobromide | 19 | $13,041 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $12,564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,083 | $253,913149 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,163 | $150,039165 claims |
| PfizerEliquis | $125 | $131,181120 claims |
| Lilly USA, LLCMounjaro | $364 | $86,70872 claims |
| GSKTrelegy Ellipta | $536 | $67,86087 claims |
| Boehringer IngelheimJardiance | $197 | $59,93037 claims |
| Johnson & JohnsonXarelto | $63 | $55,07372 claims |
| Astellas Pharma US IncMyrbetriq | $115 | $23,38928 claims |
| NovartisEntresto | $56 | $20,62921 claims |
| AbbVieLinzess, Synthroid | $838 | $18,87154 claims |
| MerckJanuvia, Belsomra | $264 | $16,12125 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $237 | $13,04119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Tell City
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
- Jeffrey HiltzMuncie$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.